Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA) announced on Nov 3, 2025 that it received a $30 million development milestone payment from Kyowa Kirin after dosing the first patient in the second of two frontline KOMET-017 Phase 3 trials of ziftomenib. This follows a prior $30 million milestone in October 2025 and brings total milestone receipts to $105 million to date. Kura stated it expects up to $315 million in additional near-term milestones under the collaboration.
KOMET-017 (NCT07007312) comprises two independent, global, randomized, double-blind, placebo-controlled Phase 3 trials evaluating once-daily oral menin inhibitor ziftomenib with both intensive and non-intensive chemotherapy in newly diagnosed NPM1-mutated or KMT2A-rearranged AML.
Positive
- $30M milestone received on Nov 3, 2025
- Total milestone cash received: $105M to date
- Up to $315M in additional near-term milestones expected
- KOMET-017 comprises two independent Phase 3 registrational trials
Negative
- None.
News Market Reaction 43 Alerts
On the day this news was published, KURA declined 4.87%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.0% during that session. Argus tracked a trough of -8.9% from its starting point during tracking. Our momentum scanner triggered 43 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $45M from the company's valuation, bringing the market cap to $883M at that time.
Data tracked by StockTitan Argus on the day of publication.
– Milestone triggered by dosing of first patient in the second of two frontline AML Phase 3 clinical trials –
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced receipt of a
KOMET-017 (NCT07007312) comprises two independent, global, randomized double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). Kura believes KOMET-017 is the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding the therapeutic potential of ziftomenib, the KOMET-017 trial being the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings, and anticipated near-term milestone payments under Kura’s collaboration agreement with Kyowa Kirin. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, the risk that the collaboration with Kyowa Kirin is unsuccessful, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
What milestone did Kura (KURA) announce on Nov 3, 2025?
How much milestone cash has Kura (KURA) received from Kyowa Kirin to date?
How much additional milestone funding does Kura (KURA) expect under the collaboration?
What is KOMET-017 and which AML populations does it target?
What triggered the $30 million milestone payment to Kura (KURA)?
Is ziftomenib an approved drug in KOMET-017 trials?
